TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Tiziana Life Sciences ( (TLSA) ).
On September 30, 2025, Tiziana Life Sciences announced its invitation to the prestigious J.P. Morgan Asset Management Life Science Innovation Forum 2025 in Riyadh, Saudi Arabia, held on October 1–2, 2025. This event provides Tiziana with a platform to engage with global investors and explore strategic collaborations, potentially enhancing its market positioning and advancing its mission to deliver next-generation immunotherapy solutions.
The most recent analyst rating on (TLSA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Tiziana Life Sciences stock, see the TLSA Stock Forecast page.
More about Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using innovative drug delivery technologies. The company specializes in immunomodulation therapies, with its lead candidate being intranasal foralumab, a fully human anti-CD3 monoclonal antibody, which is currently in clinical development for treating neuroinflammatory and neurodegenerative diseases.
Average Trading Volume: 391,515
Technical Sentiment Signal: Buy
Current Market Cap: $236.9M
For detailed information about TLSA stock, go to TipRanks’ Stock Analysis page.